Congratulations to iBIO member Tempus AI and its founder, Eric Lefkofsky, on their remarkable achievement!

We are thrilled to announce that Tempus AI, a trailblazing precision-medicine startup, is set to make its highly anticipated debut on the stock market this Friday, June 14, 2024. Trading under the ticker symbol TEM, Tempus AI has already made waves by raising an impressive $410 million in its initial public offering (IPO), resulting in a valuation of approximately $6.2 billion, as reported by Crain’s.

Founded by visionary entrepreneur Eric Lefkofsky in 2015, Tempus AI has revolutionized the healthcare industry by providing cutting-edge genomic-sequencing services to healthcare providers. By leveraging advanced data analysis and genomic information, Tempus AI empowers physicians to develop personalized treatment plans tailored to each patient’s unique genetic profile. This groundbreaking approach has the potential to significantly improve the treatment of cancers and other complex medical conditions.

The success of Tempus AI’s IPO is a testament to the company’s innovative vision, dedicated team, and unwavering commitment to advancing precision medicine. This milestone not only validates the immense value Tempus AI brings to the healthcare industry but also positions the company for continued growth and impact in the years to come.

As a member of the iBIO community, we extend our heartfelt congratulations to Eric Lefkofsky and the entire Tempus AI team. Your tireless efforts and groundbreaking work are truly inspiring, and we look forward to witnessing the transformative impact you will undoubtedly have on patient care and the future of precision medicine.

Read the Chicago Crain’s article announcing the IPO